All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 154 of 206 pages ‹ First < 152 153 154 155 156 > Last ›
HSL2256
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2490
Briggs DR.
The regulation of herbal medicines in Australia.
Toxicology 2002 Dec 27;181-182:565-70
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12505367
HSL19519
Pear R
Drug Makers Battle A U.S. Plan to Curb Rewards for Doctors
The New York Times 2002 Dec 26
http://www.nytimes.com/2002/12/26/politics/26DRUG.html
HSL1923
Thorat MA .
Grading the competing interests
BMJ 2002 Dec 20;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL17385
Friscolanti M
Discount Drugs of Canada in Florida: 'Unlicensed pharmacies' spring up in Sunshine State
National Post 2002 Dec 20
HSL2005
Freudenheim M.
The Media Business: Advertising; Influencing Doctor's Orders
New York Times 2002 Dec 17
HSL2499
Ashcroft RE.
Conflicts of interest
BMJ 2002 Dec 17;325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL19520
Relman AS, Angell M
America's Other Drug Problem: How the drug industry distorts medicine and politics.
The New Republic 2002 Dec 16
www.commercialalert.org/relmanangell.pdf
HSL2248
Kuczynski A.
Treating disease with a famous face.
New York Times 2002 Dec 15
http://www.nytimes.com/2002/12/15/fashion/15DISE.html
HSL1934
Smith R.
Making progress with competing interests.
BMJ 2002 Dec 14;325:(7377):1375-6
http://bmj.com/cgi/reprint/325/7377/1375.pdf
HSL2483
Chaudhry S, Schroter S, Smith R, Morris J.
Does declaration of competing interests affect readers' perceptions? A randomised trial.
BMJ 2002 December 14;325:1391-1392
http://bmj.com/cgi/content/full/325/7377/1391
HSL17881
Ferriman A
Novartis breached code after doctors say it 'invented' a disease
BMJ 2002 Dec 14;325:(7377):1379
http://www.bmj.com/cgi/content/extract/325/7377/1379
HSL17882
Gottlieb S
Congress criticises drugs industry for misleading advertising
BMJ 2002 Dec 14;325:(7377):1379
http://www.bmj.com/cgi/content/extract/325/7377/1379/a
HSL1812
Collective action is good for you
University of Sussex Bulletin 2002 Dec 12
http://www.sussex.ac.uk/press_office/bulletin/13dec02/article3.shtml
HSL1970
Petersen M.
Less return in marketing of medicines, a study says
New York Times 2002 Dec 12
http://www.nytimes.com/2002/12/12/business/12DRUG.html
HSL1033
Associated Press.
Ex-Lilly Workers Claim Corporate Backing
2002 Dec 11
HSL2001
Ex - Lilly Workers Claim Corporate Backing
THE ASSOCIATED PRESS 2002 Dec 11
HSL10669
Cohen GL.
Fiction: Off-label.
Neurology 2002 Dec 10;59:(11):1818-20
http://www.neurology.org/cgi/content/full/59/11/1818
HSL2028
arsa L.
Anti-anxiety drug market just keeps growing
Los Angeles Times 2 02 Dec
htp://ww.gomempis.com/
ca/healh_and_f tness/aticle/0,1426,MCA_522_1596546,00.html
HSL1823
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4;:A1,:
HSL2000
Warner J.
Misleading Drug Ads Persist
Medscape Medical News 2002 Dec 4
http://www.medscape.com/viewarticle/445686
HSL17380
Consumers Consider Prescription Drug Advertisements 'Useful,' Survey Finds
California Healthline 2002 Dec 4
HSL17390
Quick Take: New study finds DTC drive to Web yields new prescribers
Eyeforpharma.com 2002 Dec 3
http://www.eyeforpharma.com/print.asp?news=26635
HSL5378
Shilling C.
Culture, the 'sick role' and the consumption of health.
Br J Sociol 2002 Dec 01;53:(4):621-38
http://journalsonline.tandf.co.uk/(20tfmkfypf4rf2vfye5dnqr2)/app/home/contribution.asp?referrer=parent&backto=issue,7,11;journal,5,20;linkingpublicationresults,1:103801,1
HSL1616
Tormala ZL, Petty RE.
What doesn't kill me makes me stronger: the effects of resisting persuasion on attitude certainty.
J Pers Soc Psychol 2002 Dec;83:(6):1298-313
http://content.apa.org/journals/psp/83/6/1298
HSL1828
Chakrabarti A, Fleisher WP, Staley D, Calhoun L.
Interactions of staff and residents with pharmaceutical industry: a survey of psychiatric training program policies.
Ann R Coll Physicians Surg Can 2002 Dec;35:(8):
HSL1846
Orme M, Frolich J, Vrhovac B; Education Sub-Committee of the European Association for Clinical Pharmacology and Therapeutics.
Towards a core curriculum in clinical pharmacology for undergraduate medical students in Europe.
Eur J Clin Pharmacol 2002 Dec;58:(9):635-40
http://www.springerlink.com/app/home/contribution.asp?wasp=d5507396d41e4c958bbfd93f7f098d21&referrer=parent&backto=issue,11,12;journal,31,106;linkingpublicationresults,1:100413,1
HSL1848
Katz HP, Goldfinger SE, Fletcher SW.
Academia-industry collaboration in continuing medical education: description of two approaches.
J Contin Educ Health Prof 2002 Win;22:(1):43-54
HSL2026
Miles MP, Munilla LS, Covin JG.
The Constant Gardener revisited: the effect of social blackmail on the marketing concept, innovation, and entrepreneurship.
J Bus Ethics 2002 Dec;41:(3):287-95
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12755097
HSL2252
Klassen TP.
Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?
Arch Pediatr Adolesc Med 2002 Dec;156:(12):1180-1
http://archpedi.ama-assn.org/cgi/content/full/156/12/1180
HSL2456
Hollis A.
The importance of being first: evidence from Canadian generic pharmaceuticals.
Health Econ 2002 Dec;11:(8):723-34
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457372
HSL2495
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Quality of global e-pharmacies: can we safeguard consumers?
Eur J Clin Pharmacol 2002 Dec;58:(9):567-72
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12168510
HSL10475
Lampl C, Buzath A, Yazdi K, Sandor PS.
Ergot and triptan overuse in Austria--an evaluation of clinical data and cost.
Cephalalgia 2002 Dec;22:(10):807-11
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1468-2982.2002.00442.x
HSL10652
Avouac B.
Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
Joint Bone Spine 2002 Dec;69:(6):534-7
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W90-488N2YG-3&_user=10&_coverDate=12%2F31%2F2002&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=23cac00b44f2455dc037e841e18071f3
HSL10656
Carroll NV.
How effectively do managed care organizations influence prescribing and dispensing decisions?
Am J Manag Care 2002 Dec;8:(12):1041-54
http://www.ajmc.com/Article.cfm?ID=113&CFID=8980495&CFTOKEN=81996035
HSL10658
Dargan P, Jones A.
Paracetamol: balancing risk against benefit.
QJM 2002 Dec;95:(12):831-2
http://qjmed.oxfordjournals.org/cgi/content/full/95/12/831
HSL16362
Weatherby LB, Nordstrom BL, Fife D, Walker AM.
The impact of wording in 'Dear doctor' letters and in black box labels.
Clin Pharmacol Ther 2002 Dec;72:(6):735-42
http://www.nature.com/clpt/journal/v72/n6/abs/clpt2002134a.html
HSL16745
Wolfe SM.
Drug safety withdrawals: who is responsible for notifying patients?
Pharmacoepidemiol Drug Saf 2002 Dec;11:(8):641-2
http://www.ncbi.nlm.nih.gov/pubmed/12512237
HSL17883
Josefson D
Drug advertisers face scrutiny after potentially breaking FDA rules
BMJ 2002 Nov 30;325:(7375):1262
http://www.bmj.com/cgi/content/extract/325/7375/1262/a
HSL1922
Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J.
[A case report of mania precipitated by use of DHEA].
Encephale. 2002 Nov-Dec 28;6:563-6
http://www.masson.fr/masson/portal/main_gab_art.ccn;jsessionid=E06B58A1556551049EE6D31F834D930B.mastin3?CodeProduct4=539&CodeRevue4=ENC&Path=REVUE/ENC/2002/28/6/ARTICLE111061972019.xml&Locations=
HSL2246
Labarre R.
Doctors and Industry
The New York Times 2002 Nov 28
http://www.nytimes.com/2002/11/28/opinion/L28DRUG.html
HSL1068
PR Newswire Association LLC
Pharmaceutical giants over-invest in promotion
2002 Nov 27
http://www.bioportfolio.com/news/report_1.htm
HSL1999
Zuckerman D.
Hype in Health Reporting
AlterNet 2002 Nov 25
http://www.alternet.org/story.html?StoryID=14638
HSL2469
Dukes MN.
Accountability of the pharmaceutical industry.
Lancet 2002 Nov 23;360:(9346):1682-4
http://linkinghub.elsevier.com/retrieve/pii/S0140673602115996
HSL2251
Klausner JD, Kim A, Kent C.
Are HIV drug advertisements contributing to increases in risk behavior among men in San Francisco, 2001?
AIDS 2002 Nov 22;16:(17):2349-50
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12441813
HSL3810
Petersen M.
Madison Ave. plays growing role in drug research
New York Times 2002 Nov 22
http://www.nytimes.com/2002/11/22/business/22DRUG.html
HSL1920
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177:(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL3811
Gazarian M, Kaye KI.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177:(10):572-3
HSL5454
Murphy S.
Gifts seen effective by drug company reps
Boston Globe 2002 Nov 17
HSL19521
Swidey N
The costly case of the purple pil
The Boston Globe 2002 Nov 17
http://www.boston.com/globe/magazine/2002/1117/coverstory.htm
HSL2459
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16;360:(9345):1590-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12443614
HSL3813
Smith R.
New BMJ policy on economic evaluations.
BMJ 2002 Nov 16;325:(7373):1124
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=12433741
HSL17885
Gottlieb S
Serious adverse events associated with perinatal drugs
BMJ 2002 Nov 16;325:(7373):1132
http://www.bmj.com/cgi/content/extract/325/7373/1132
HSL2501
Abraham J.
The pharmaceutical industry as a political player.
Lancet 2002 Nov 9;360:(9344):1498-502
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12433532
HSL17884
Campion EW.
Suspicions about the safety of vaccines.
N Engl J Med 2002 Nov 7;347:(19):1474-5
http://content.nejm.org/cgi/content/extract/347/19/1474
HSL2006
Viva Viagra
2002 Nov 2
HSL2447
James A.
Medicines, society, and industry.
Lancet 2002 Nov 2;360:(9343):1346
http://www.thelancet.com/journal/vol360/iss9343/full/llan.360.9343.editorial_and_review.22990.1
HSL2479
Collier J, Iheanacho I.
The pharmaceutical industry as an informant.
Lancet 2002 Nov 2;360:(9343):1405-9
http://www.thelancet.com/journal/vol/iss/full/llan.360.9343.editorial_and_review.22976.1
HSL17887
James A.
Medicines, society, and industry.
Lancet 2002 Nov 2;360:(9343):1346
http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(02)11416-4
HSL17888
Ed.
An innovative challenge to the pharmaceutical industry
The Lancet 2002 Nov 2;360:(9343):1341
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11417-6/fulltext
HSL17889
Hopkins Tanne J
Better standards needed for industry sponsored clinical trials
BMJ 2002 Nov 2;325:(7371):985
http://www.bmj.com/cgi/content/extract/325/7371/985/a
HSL17890
Watson R
MEPs reject US-style direct advertising of drugs
BMJ 2002 Nov 2;325:(7371):990
http://www.bmj.com/cgi/content/extract/325/7371/990/a
HSL2504
Drug companies offer DM programs for MS patients.
Dis Manag Advis. 2002 Nov 01;8:(11):165-8, 161
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12506456
HSL414
Brodie M, Levitt L.
Drug advertising: the right or wrong prescription for our ailments?
Nat Rev Drug Discov 2002 Nov;1:(11):916-20
http://www.nature.com/nrd/journal/v1/n11/abs/nrd943_fs.html;jsessionid=E0C11BC508A8240CE88E82D780D4A2C9
HSL1258
Wirth M, Scherer D.
Patient's perceptions of doctors' relationships with pharmaceutical companies
Healthy Skepticism International News 2002 Nov;20:(11):
www.healthyskepticism.org
HSL1966
Rakatansky H.
Review article: gastroenterology and the pharmaceutical industry.
Aliment Pharmacol Ther 2002 Nov;16:(11):1859-66
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.2002.01362.x
HSL2464
Glasgow C, Schommer JC, Gupta K, Pierson K.
Promotion of prescription drugs to consumers: case study results.
J Manag Care Pharm 2002 Nov-Dec;8:(6):512-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14613384
HSL2492
Boltri JM, Gordon ER, Vogel RL.
Effect of antihypertensive samples on physician prescribing patterns.
Fam Med 2002 Nov-Dec;34:(10):729-31
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448641
HSL10621
Macia MA, Carvajal A, del Pozo JG, Vera E, del Pino A.
Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System.
Clin Pharmacol Ther 2002 Nov;72:(5):596-7
HSL10662
Biswas PN, Wilton LV, Shakir SW.
The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
J Hum Hypertens 2002 Nov;16:(11):795-803
http://www.nature.com/jhh/journal/v16/n11/abs/1001490a.html
HSL10663
Shiffman S, Gorsline J, Gorodetzky CW.
Efficacy of over-the-counter nicotine patch.
Nicotine Tob Res 2002 Nov;4:(4):477-83
http://www.informaworld.com/smpp/content?content=10.1080/1462220021000018416
HSL10668
Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Eur J Clin Pharmacol 2002 Nov;58:(8):495-500
http://www.springerlink.com/content/c52uy58a4h0jd0k2/
HSL16744
Lurie P, Wolfe SM.
Continuing exposure to hexavalent chromium, a known lung carcinogen: an analysis of OSHA compliance inspections, 1990-2000.
Am J Ind Med 2002 Nov;42:(5):378-83
http://www3.interscience.wiley.com/journal/99017825/abstract?CRETRY=1&SRETRY=0
HSL17886
Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ.
Reported adverse drug events in infants and children under 2 years of age.
Pediatrics 2002 Nov;110:(5):e53
http://pediatrics.aappublications.org/cgi/content/full/110/5/e53
HSL20270
Croskerry P
Achieving quality in clinical decision making: cognitive strategies and detection of bias
Acad Emerg Med 2002 Nov;9:(11):1184-204
http://www.ncbi.nlm.nih.gov/pubmed/12414468
HSL17892
Steinbrook R.
Testing medications in children.
N Engl J Med 2002 Oct 31;347:(18):1462-70
http://content.nejm.org/cgi/content/extract/347/18/1462
HSL17891
Ed.
Drug marketing: unsafe at any dose?
CMAJ 2002 Oct 29;167:(9):981,
http://www.cmaj.ca/cgi/content/full/167/9/981
HSL2477
Corbett J.
Drug pushers - the campaign for Glivec funding
New Zealand Herald 2002 Oct 26
http://www.nzherald.co.nz/storydisplay.cfm?storyID=3001076
HSL17379
Milloy S
Beware Drug Company Marketing
FOX News 2002 Oct 25
http://www.foxnews.com/story/0,2933,66645,00.html
HSL1959
Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM.
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.
N Engl J Med 2002 Oct 24;347:(17):1335-41
http://content.nejm.org/cgi/content/abstract/347/17/1335
HSL17893
Moses H 3rd, Braunwald E, Martin JB, Thier SO.
Collaborating with industry--choices for the academic medical center.
N Engl J Med 2002 Oct 24;347:(17):1371-5
http://content.nejm.org/cgi/content/extract/347/17/1371
HSL17894
Benson J, Britten N
Patients' decisions about whether or not to take antihypertensive drugs: qualitative study
BMJ 2002 Oct 19;325:(7369):873
http://www.bmj.com/cgi/content/abstract/325/7369/873
HSL17895
Patients make balanced decisions whether to take drugs
BMJ 2002 Oct 19;325:(7369):
http://www.bmj.com/cgi/content/full/325/7369/0/b
HSL1994
O'Meara K P
Medical Research To Die For
Insight magazine 2002 Oct 15
HSL17896
Marwick C
US tackles drug company gifts to doctors
BMJ 2002 Oct 12;325:(7368):795
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1169556/
HSL19958
Baker D, Chatani N
Promoting Good Ideas on Drugs: Are Patents the Best Way?
cepr 2002 Oct 11
http://www.cepr.net/index.php/publications/reports/promoting-good-ideas-on-drugs-are-patents-the-best-way/
HSL17395
Barclay L
OIG Guidelines: An Expert Interview With Arthur Palamara, MD
Medscape Medical News 2002 Oct 9
HSL17898
Joyce GF, Escarce JJ, Solomon MD, Goldman DP.
Employer drug benefit plans and spending on prescription drugs.
JAMA 2002 Oct 9;288:(14):1733-9
http://jama.ama-assn.org/cgi/content/full/288/14/1733
HSL1992
Seglin J.
Just Saying No to Gifts From Drug Makers
The New York Times 2002 Oct 8
HSL1928
Sweet M.
Conference promotion in the media: serving whose interests?
Med J Aust 2002 Oct 7;177:(7):341-2
http://www.mja.com.au/public/issues/177_07_071002/swe10463_fm.html
HSL1990
Moore K.
Drug companies push pills to doctors
Morning Journal Writers 2002 Oct 7
HSL1998
Croasdale M.
CME providers gear up to comply with PhRMA code: Eager to follow new guidelines separating drug promotions from continuing medical education, CME presenters' questions outpace answers at a meeting of drug industry and education leaders.
AMNews 2002 Oct 7
HSL17897
Kapp C.
Counterfeit drug problem
Lancet 2002 Oct 5;360:(9339):1080
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)11185-8/fulltext
HSL1196
Braithwaite J.
Restorative Justice and Responsive Regulation
Oxford: Oxford University Press 2002
http://www.oup.co.uk/isbn/0-19-515839-3
HSL2307
Cassels A.
Consumer drug advertising leads to MD backlash in Holland.
CMAJ 2002 Oct 1;167:(7):793
http://www.cmaj.ca/cgi/content/full/167/7/793
HSL5322
Coast J, Smith R, Karcher AM, Wilton P, Millar M.
Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?
Health Econ 2002 Oct 01;11:(7):637-47
http://www3.interscience.wiley.com/cgi-bin/abstract/93521364/ABSTRACT
HSL19522
Pear R
Drug Industry Is Told to Stop Gifts to Doctors
The New York Times 2002 Oct 1
http://www.nytimes.com/2002/10/01/national/01DRUG.html
HSL1419
Jureidini J.
Does the International Consensus Statement on ADHD leave room for healthy scepticism?
Eur Child Adolesc Psychiatry 2002 Oct;11:(5):240
HSL1893
Brotons C, Moral I, Ribera A, Cascant P, Iglesias M, Permanyer-Miralda G, Ferreira Gonzalez I, Soler-Soler J.
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention.]
Rev Esp Cardiol 2002 Oct;55:(10):1042-51
http://www.revespcardiol.org/cgi-bin/wdbcgi.exe/cardio/cardioeng.acceso_full.alta
HSL2201
Maitland I.
Priceless goods: how should life-saving drugs be priced?
Bus Ethics Q 2002 Oct;12:(4):451-80
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12708456
Page 154 of 206 pages ‹ First < 152 153 154 155 156 > Last ›
